

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5100193

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
KANDASWAMY VIJAYAN	07/21/2015
EUGENE TU	07/21/2015
MARK A. BERNARD	07/21/2015
RECEIVING PARTY DATA	
Name:	OMNIOME, INC.
Street Address:	10575 ROSELLE STREET
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16046707
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	patent@omniome.com
Correspondent Name:	OMNIOME, INC.
Address Line 1:	10575 ROSELLE STREET
Address Line 4:	SAN DIEGO, CALIFORNIA 92121
ATTORNEY DOCKET NUMBER:	OMNI-001A.UTL
NAME OF SUBMITTER:	ROSALYN M. ESPEJO
SIGNATURE:	/ROSALYN M. ESPEJO/
DATE SIGNED:	08/21/2018
Total Attachments: 5	
source=OMNI-001A.UTL_Assignment_from_parent#page1.tif	
source=OMNI-001A.UTL_Assignment_from_parent#page2.tif	
source=OMNI-001A.UTL_Assignment_from_parent#page3.tif	
source=OMNI-001A.UTL_Assignment_from_parent#page4.tif	
source=OMNI-001A.UTL_Assignment_from_parent#page5.tif	

ASSIGNMENT
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application entitled

“NUCLEIC ACID SEQUENCING METHODS AND SYSTEMS,”

the specification of which is provided with this Assignment and identified by the Attorney Docket No. above. (Serial No. 14/805,381 filed on July 21, 2015)


For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Omniome, Inc., a corporation having a principal place of business at 4225 Executive Square, Suite 440, La Jolla, California 92037 (“Assignee”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.
 6. Authorize Kilpatrick Townsend & Stockton to insert above the application number and filing date of the above-described patent application when known.

Signed on the dates indicated beside our signatures.

Signature: _____




Date: _____

7/21/15

KANDASWAMY VIJAYAN

WITNESSED BY:


Name: _____

 Michael Nguyen

Date: _____


7/21/15

Name: _____

 Maxim Abashin


Date: _____

7/21/15


Signature: 
EUGENE TU

Date: 7-21-15

WITNESSED BY:

Name:  Michael Nguyen

Date: 7/21/15

Name:  Maxim Abastin

Date: 7/21/15

Signature: Mark Bernard

Date: 7-21-2015

MARK A. BERNARD

WITNESSED BY:

Name: Michael Mayson MICHAEL MAYSON

Date: 7/21/15

Name: Maksim Abashin Maksim Abashin

Date: 7/21/15


ASSIGNMENT
NUCLEIC ACID SEQUENCING METHODS AND SYSTEMS
Attorney Docket No. 97128-951409-009US1
Page 5 of 5

Accepted and Agreed to By:

OMNIOME, INC

Date: 7/21/15

By:



KARADASWAMY VISAYAN

Name:

Title:

CEO